Breaking News Instant updates and real-time market news.

PRVB

Provention Bio

$6.48 /

-0.08 (-1.22%)

07:33
09/13/21
09/13
07:33
09/13/21
07:33

Provention Bio provides update on teplizumab BLA resubmission

Provention Bio provided an update on the status and timing of its ongoing efforts to address FDA considerations cited in the Complete Response Letter issued to the company by the FDA on July 2. The company has completed the collection of data from a PK/PD substudy in the ongoing PROTECT Phase 3 trial in newly diagnosed T1D patients to determine comparability between the company's planned commercial drug product and drug product originating from drug substance manufactured for historical trials of teplizumab. During ongoing informal discussions with the FDA to finalize and agree upon the design of the population PK model that will generate the PK parameters comparing drug products, the FDA has recommended that the company request a formal Type A meeting and submit briefing documents related to the population PK model. The objective of this meeting with the FDA is to agree on the PK model's design prior to the company populating the model with relevant PK data collected from the PROTECT substudy. The company is working towards a request and submission to allow this Type A meeting to occur in the fourth quarter of this year. Additionally, the company disclosed preliminary PD marker information upon therapeutic dosing of teplizumab from the substudy data that the company believes are supportive, although not determinative, of comparability between the two drug products. The FDA has not yet opined on these data or their significance, and the company looks forward to discussing with the FDA. These PD markers include lymphocyte counts, CD3 receptor occupancy and T-cell activation. The company also recently completed a Type A meeting with the FDA to discuss several additional considerations related to product quality that were cited in the CRL. The company continues to believe that the product quality CRL considerations have either already been addressed by prior amendments to the BLA or are addressable in the short term. As it relates to the deficiencies noted during the recent general inspection at a fill/finish facility used by the dcompany mentioned in the CRL, this facility's inspection has since been closed out by the FDA in August of 2021. "We believe we are making significant progress in our work to address the observations cited by the FDA in the CRL for teplizumab we received in July and we will continue to work with the sense of urgency that the patient community and our investors expect of us," said Ashleigh Palmer, co-founder and CEO of Provention Bio. "We are encouraged by our interactions with the FDA and look forward to finalizing, to the FDA's satisfaction, the design of the population PK model that will be used to further determine comparability, as well as evaluate the clinical relevance of the outputs. Additionally we are encouraged by the consistent incremental PD marker data that we are sharing today."

  • 27

    Sep

  • 14

    Jan

PRVB Provention Bio
$6.48 /

-0.08 (-1.22%)

07/09/21 Chardan
Provention Bio coverage transferred at Chardan
05/28/21 Chardan
Provention Bio price target lowered to $22.50 from $35 at Chardan
05/25/21 SVB Leerink
Provention Bio briefing documents a positive, says SVB Leerink
05/07/21 Cantor Fitzgerald
Provention Bio price target lowered to $19 from $25 at Cantor Fitzgerald

TODAY'S FREE FLY STORIES

Initiation
Vor Biopharma initiated with an Outperform at Baird » 16:17
12/02/21
12/02
16:17
12/02/21
16:17
VOR

Vor Biopharma

$13.08 /

+1.71 (+15.04%)

Baird analyst Jack Allen…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
VOR Vor Biopharma
$13.08 /

+1.71 (+15.04%)

VOR Vor Biopharma
$13.08 /

+1.71 (+15.04%)

12/01/21 Oppenheimer
Vor Biopharma initiated with an Outperform at Oppenheimer
10/19/21 JMP Securities
Vor Biopharma initiated with an Outperform at JMP Securities
07/08/21 Stifel
Vor Biopharma, Janssen collaboration benefits both parties, says Stifel
03/25/21 B. Riley Securities
Vor Biopharma initiated with a Buy at B. Riley Securities
VOR Vor Biopharma
$13.08 /

+1.71 (+15.04%)

  • 05
    Feb
Earnings
Guidewire sees Q2 revenue $195M-$199M, consensus $189.57M » 16:16
12/02/21
12/02
16:16
12/02/21
16:16
GWRE

Guidewire

$117.11 /

+3.88 (+3.43%)

Sees Q2 adjusted…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
GWRE Guidewire
$117.11 /

+3.88 (+3.43%)

GWRE Guidewire
$117.11 /

+3.88 (+3.43%)

11/22/21 Barclays
Duck Creek Technologies upgraded to Overweight from Equal Weight at Barclays
10/04/21 BofA
Guidewire downgraded to Underperform from Neutral at BofA
09/03/21 JPMorgan
Guidewire price target raised to $160 from $145 at JPMorgan
09/03/21 BTIG
Guidewire price target raised to $138 from $130 at BTIG
GWRE Guidewire
$117.11 /

+3.88 (+3.43%)

GWRE Guidewire
$117.11 /

+3.88 (+3.43%)

GWRE Guidewire
$117.11 /

+3.88 (+3.43%)

Earnings
Ooma reports Q3 EPS 13c, consensus 9c » 16:16
12/02/21
12/02
16:16
12/02/21
16:16
OOMA

Ooma

$19.05 /

+0.23 (+1.22%)

Reports Q3 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
OOMA Ooma
$19.05 /

+0.23 (+1.22%)

OOMA Ooma
$19.05 /

+0.23 (+1.22%)

09/03/21 B. Riley
Ooma price target raised to $27.50 from $24 at B. Riley
09/03/21 Benchmark
Ooma price target raised to $30 from $27 at Benchmark
09/03/21 JMP Securities
Ooma price target raised to $27 from $22 at JMP Securities
05/27/21 B. Riley
Ooma price target raised to $24 from $23.50 at B. Riley
OOMA Ooma
$19.05 /

+0.23 (+1.22%)

OOMA Ooma
$19.05 /

+0.23 (+1.22%)

Earnings
Asana sees Q4 EPS (28c)-(27c), consensus (27c) » 16:16
12/02/21
12/02
16:16
12/02/21
16:16
ASAN

Asana

$91.01 /

+1.05 (+1.17%)

Sees Q4 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
ASAN Asana
$91.01 /

+1.05 (+1.17%)

ASAN Asana
$91.01 /

+1.05 (+1.17%)

11/18/21 Piper Sandler
Asana price target raised to $140 from $85 at Piper Sandler
11/04/21 Jefferies
Asana downgraded to Hold from Buy at Jefferies
10/21/21 KeyBanc
Asana price target raised to $143 from $85 at KeyBanc
10/06/21 Jefferies
Asana CEO's share buys 'a great indicator' of momentum, says Jefferies
ASAN Asana
$91.01 /

+1.05 (+1.17%)

ASAN Asana
$91.01 /

+1.05 (+1.17%)

ASAN Asana
$91.01 /

+1.05 (+1.17%)

ASAN Asana
$91.01 /

+1.05 (+1.17%)

Initiation
ESS Inc. initiated with an Outperform at Oppenheimer » 16:16
12/02/21
12/02
16:16
12/02/21
16:16
GWH

ESS Inc.

$15.82 /

+0.24 (+1.54%)

Oppenheimer analyst Colin…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
GWH ESS Inc.
$15.82 /

+0.24 (+1.54%)

GWH ESS Inc.
$15.82 /

+0.24 (+1.54%)

11/30/21 Canaccord
ESS Inc. initiated with a Buy at Canaccord
11/01/21 Cowen
ESS Tech initiated with an Outperform at Cowen
10/21/21 Loop Capital
Loop starts 'energy transition' play ESS with Buy, $29 price target
10/21/21 Loop Capital
ESS Tech initiated with a Buy at Loop Capital
GWH ESS Inc.
$15.82 /

+0.24 (+1.54%)

Hot Stocks
Protagonist Therapeutics announces selection of PN-235 into Phase 2 development » 16:16
12/02/21
12/02
16:16
12/02/21
16:16
PTGX

Protagonist Therapeutics

$32.67 /

+1.67 (+5.39%)

, JNJ

Johnson & Johnson

$157.08 /

-1.06 (-0.67%)

Protagonist Therapeutics…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
PTGX Protagonist Therapeutics
$32.67 /

+1.67 (+5.39%)

JNJ Johnson & Johnson
$157.08 /

-1.06 (-0.67%)

PTGX Protagonist Therapeutics
$32.67 /

+1.67 (+5.39%)

11/15/21 JMP Securities
Protagonist Therapeutics price target raised to $70 from $60 at JMP Securities
11/04/21 Piper Sandler
Piper 'pleasantly surprised' by Protagonist Therapeutics' ASH abstracts
10/13/21 JMP Securities
Protagonist Therapeutics price target raised to $60 from $47 at JMP Securities
10/12/21 JPMorgan
JPMorgan upgrades Protagonist after 'rapid' clinical hold removal
JNJ Johnson & Johnson
$157.08 /

-1.06 (-0.67%)

11/29/21 Credit Suisse
Credit Suisse stays Outperform on J&J as intra-quarter checks find pharma upside
11/09/21 Mizuho
Alkermes price target lowered to $33 from $36 at Mizuho
11/08/21 Morgan Stanley
Morgan Stanley bullish on 2seventy Bio, initiates with an Overweight
10/20/21 Raymond James
Johnson & Johnson price target lowered to $178 from $183 at Raymond James
PTGX Protagonist Therapeutics
$32.67 /

+1.67 (+5.39%)

JNJ Johnson & Johnson
$157.08 /

-1.06 (-0.67%)

  • 16
    Jun
  • 11
    Dec
JNJ Johnson & Johnson
$157.08 /

-1.06 (-0.67%)

PTGX Protagonist Therapeutics
$32.67 /

+1.67 (+5.39%)

JNJ Johnson & Johnson
$157.08 /

-1.06 (-0.67%)

PTGX Protagonist Therapeutics
$32.67 /

+1.67 (+5.39%)

JNJ Johnson & Johnson
$157.08 /

-1.06 (-0.67%)

Earnings
Guidewire reports Q1 adjusted EPS (21c), consensus (25c) » 16:16
12/02/21
12/02
16:16
12/02/21
16:16
GWRE

Guidewire

$117.11 /

+3.88 (+3.43%)

Reports Q1 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
GWRE Guidewire
$117.11 /

+3.88 (+3.43%)

GWRE Guidewire
$117.11 /

+3.88 (+3.43%)

11/22/21 Barclays
Duck Creek Technologies upgraded to Overweight from Equal Weight at Barclays
10/04/21 BofA
Guidewire downgraded to Underperform from Neutral at BofA
09/03/21 JPMorgan
Guidewire price target raised to $160 from $145 at JPMorgan
09/03/21 BTIG
Guidewire price target raised to $138 from $130 at BTIG
GWRE Guidewire
$117.11 /

+3.88 (+3.43%)

GWRE Guidewire
$117.11 /

+3.88 (+3.43%)

GWRE Guidewire
$117.11 /

+3.88 (+3.43%)

Earnings
Asana reports Q3 EPS (23c), consensus (26c) » 16:15
12/02/21
12/02
16:15
12/02/21
16:15
ASAN

Asana

$91.01 /

+1.05 (+1.17%)

Reports Q3 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
ASAN Asana
$91.01 /

+1.05 (+1.17%)

ASAN Asana
$91.01 /

+1.05 (+1.17%)

11/18/21 Piper Sandler
Asana price target raised to $140 from $85 at Piper Sandler
11/04/21 Jefferies
Asana downgraded to Hold from Buy at Jefferies
10/21/21 KeyBanc
Asana price target raised to $143 from $85 at KeyBanc
10/06/21 Jefferies
Asana CEO's share buys 'a great indicator' of momentum, says Jefferies
ASAN Asana
$91.01 /

+1.05 (+1.17%)

ASAN Asana
$91.01 /

+1.05 (+1.17%)

ASAN Asana
$91.01 /

+1.05 (+1.17%)

ASAN Asana
$91.01 /

+1.05 (+1.17%)

Initiation
Ecolab resumed with an In Line at Evercore ISI » 16:15
12/02/21
12/02
16:15
12/02/21
16:15
ECL

Ecolab

$224.52 /

+4.18 (+1.90%)

Evercore ISI analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ECL Ecolab
$224.52 /

+4.18 (+1.90%)

ECL Ecolab
$224.52 /

+4.18 (+1.90%)

10/27/21
Fly Intel: Top five analyst downgrades
10/27/21 BMO Capital
Ecolab price target raised to $246 from $223 at BMO Capital
10/27/21 JPMorgan
Ecolab downgraded to Underweight on valuation at JPMorgan
10/27/21 Deutsche Bank
Ecolab price target raised to $260 from $250 at Deutsche Bank
ECL Ecolab
$224.52 /

+4.18 (+1.90%)

ECL Ecolab
$224.52 /

+4.18 (+1.90%)

Hot Stocks
Zillow approves $750M share repurchase program » 16:15
12/02/21
12/02
16:15
12/02/21
16:15
Z

Zillow

$54.30 /

+1.255 (+2.37%)

Zillow Group authorized…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
Z Zillow
$54.30 /

+1.255 (+2.37%)

Z Zillow
$54.30 /

+1.255 (+2.37%)

11/22/21 Piper Sandler
October housing data positive for Redfin and Zillow, says Piper Sandler
11/19/21 Piper Sandler
Zillow Group price target lowered to $68 from $78 at Piper Sandler
11/04/21 Citi
Citi downgrades Zillow with shares in 'penalty box' on homes exit
11/03/21 Craig-Hallum
Zillow Group price target lowered to $95 from $135 at Craig-Hallum
Z Zillow
$54.30 /

+1.255 (+2.37%)

Z Zillow
$54.30 /

+1.255 (+2.37%)

Z Zillow
$54.30 /

+1.255 (+2.37%)

Z Zillow
$54.30 /

+1.255 (+2.37%)

Syndicate
AppLovin announces launch of 6.5M shares of Class A common stock » 16:15
12/02/21
12/02
16:15
12/02/21
16:15
APP

AppLovin

$90.37 /

+4.09 (+4.74%)

AppLovin Corporation…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
APP AppLovin
$90.37 /

+4.09 (+4.74%)

APP AppLovin
$90.37 /

+4.09 (+4.74%)

11/18/21
Fly Intel: Top five analyst initiations
11/18/21 Arete
AppLovin initiated with a Sell at Arete
11/12/21 Stifel
AppLovin price target raised to $125 from $110 at Stifel
11/11/21 Truist
AppLovin price target raised to $110 from $100 at Truist
APP AppLovin
$90.37 /

+4.09 (+4.74%)

  • 15
    Apr
APP AppLovin
$90.37 /

+4.09 (+4.74%)

Hot Stocks
Lyell Immunopharma announces return of Dr. Rick Klausner as board chair » 16:14
12/02/21
12/02
16:14
12/02/21
16:14
LYEL

Lyell Immunopharma

$9.46 /

+0.09 (+0.96%)

Lyell Immunopharma…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
LYEL Lyell Immunopharma
$9.46 /

+0.09 (+0.96%)

07/12/21 JPMorgan
Lyell Immunopharma initiated with an Overweight at JPMorgan
07/12/21 Morgan Stanley
Lyell Immunopharma initiated with an Overweight at Morgan Stanley
07/12/21 BofA
Lyell Immunopharma initiated with a Buy at BofA
07/12/21 Goldman Sachs
Lyell Immunopharma initiated with a Buy at Goldman Sachs
LYEL Lyell Immunopharma
$9.46 /

+0.09 (+0.96%)

  • 17
    Jun
LYEL Lyell Immunopharma
$9.46 /

+0.09 (+0.96%)

LYEL Lyell Immunopharma
$9.46 /

+0.09 (+0.96%)

Earnings
Zillow raises Q4 Homes segment revenue view to $2.3B-$2.9B from $1.7B-$2.1B » 16:13
12/02/21
12/02
16:13
12/02/21
16:13
Z

Zillow

$54.24 /

+1.2 (+2.26%)

Zillow Group announced it…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
Z Zillow
$54.24 /

+1.2 (+2.26%)

Z Zillow
$54.24 /

+1.2 (+2.26%)

11/22/21 Piper Sandler
October housing data positive for Redfin and Zillow, says Piper Sandler
11/19/21 Piper Sandler
Zillow Group price target lowered to $68 from $78 at Piper Sandler
11/04/21 Citi
Citi downgrades Zillow with shares in 'penalty box' on homes exit
11/03/21 Craig-Hallum
Zillow Group price target lowered to $95 from $135 at Craig-Hallum
Z Zillow
$54.24 /

+1.2 (+2.26%)

Z Zillow
$54.24 /

+1.2 (+2.26%)

Z Zillow
$54.24 /

+1.2 (+2.26%)

Z Zillow
$54.24 /

+1.2 (+2.26%)

Earnings
Ulta Beauty raises FY21 EPS view to $16.70-$17.10, consensus $15.19 » 16:13
12/02/21
12/02
16:13
12/02/21
16:13
ULTA

Ulta Beauty

$381.60 /

+11.27 (+3.04%)

Raises FY21 revenue view…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
ULTA Ulta Beauty
$381.60 /

+11.27 (+3.04%)

ULTA Ulta Beauty
$381.60 /

+11.27 (+3.04%)

10/20/21 Cowen
Ulta Beauty price target lowered to $440 from $490 at Cowen
10/20/21 BofA
Ulta Beauty price target lowered to $400 from $430 at BofA
10/20/21 William Blair
Ulta Beauty should be bought on yesterday's selloff, says William Blair
10/20/21 Baird
Ulta Beauty risk/reward attractive at current levels, says Baird
ULTA Ulta Beauty
$381.60 /

+11.27 (+3.04%)

ULTA Ulta Beauty
$381.60 /

+11.27 (+3.04%)

ULTA Ulta Beauty
$381.60 /

+11.27 (+3.04%)

ULTA Ulta Beauty
$381.60 /

+11.27 (+3.04%)

Hot Stocks
Federal Realty announces holding company reorganization » 16:13
12/02/21
12/02
16:13
12/02/21
16:13
FRT

Federal Realty

$127.24 /

+5.965 (+4.92%)

Federal Realty Investment…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
FRT Federal Realty
$127.24 /

+5.965 (+4.92%)

FRT Federal Realty
$127.24 /

+5.965 (+4.92%)

12/01/21 BMO Capital
Federal Realty upgraded to Outperform from Market Perform at BMO Capital
10/06/21 Deutsche Bank
Federal Realty price target raised to $140 from $129 at Deutsche Bank
09/01/21 Barclays
Federal Realty initiated with an Overweight at Barclays
08/27/21 Truist
Federal Realty price target raised to $125 from $120 at Truist
FRT Federal Realty
$127.24 /

+5.965 (+4.92%)

FRT Federal Realty
$127.24 /

+5.965 (+4.92%)

Hot Stocks
Phillips 66, British Airways announces 'sustainable aviation fuel supply deal' » 16:12
12/02/21
12/02
16:12
12/02/21
16:12
PSX

Phillips 66

$71.36 /

+2.65 (+3.86%)

The company states:…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
PSX Phillips 66
$71.36 /

+2.65 (+3.86%)

PSX Phillips 66
$71.36 /

+2.65 (+3.86%)

11/15/21 Wells Fargo
Phillips 66 price target raised to $104 from $97 at Wells Fargo
11/03/21 Goldman Sachs
Phillips 66 upgraded to Conviction Buy from Buy at Goldman Sachs
11/01/21 Raymond James
Phillips 66 Partners downgraded to Market Perform from Outperform at Raymond James
10/28/21 Credit Suisse
Credit Suisse cuts Phillips 66 Partners to Neutral on acquisition announcement
PSX Phillips 66
$71.36 /

+2.65 (+3.86%)

PSX Phillips 66
$71.36 /

+2.65 (+3.86%)

PSX Phillips 66
$71.36 /

+2.65 (+3.86%)

PSX Phillips 66
$71.36 /

+2.65 (+3.86%)

Hot Stocks
CTO Realty Growth acquires Beaver Creek Crossing in North Carolina for $70.5M » 16:12
12/02/21
12/02
16:12
12/02/21
16:12
CTO

CTO Realty Growth

$55.54 /

+0.97 (+1.78%)

CTO Realty Growth…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
CTO CTO Realty Growth
$55.54 /

+0.97 (+1.78%)

CTO CTO Realty Growth
$55.54 /

+0.97 (+1.78%)

05/28/21 BTIG
CTO Realty Growth initiated with a Buy at BTIG
05/03/21 Compass Point
CTO Realty Growth downgraded to Neutral from Buy at Compass Point
02/23/21 B. Riley Securities
CTO Realty Growth price target lowered to $65 from $67 at B. Riley Securities
Hot Stocks
Ollie's Bargain Outlet announces additional $200M to repurchase » 16:12
12/02/21
12/02
16:12
12/02/21
16:12
OLLI

Ollie's Bargain Outlet

$62.58 /

+1.43 (+2.34%)

During the third quarter…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
OLLI Ollie's Bargain Outlet
$62.58 /

+1.43 (+2.34%)

OLLI Ollie's Bargain Outlet
$62.58 /

+1.43 (+2.34%)

09/08/21
Fly Intel: Top five analyst upgrades
09/08/21 Berenberg
Ollie's Bargain Outlet upgraded to Buy on pullback at Berenberg
09/08/21 Berenberg
Ollie's Bargain Outlet upgraded to Buy from Hold at Berenberg
09/02/21 Piper Sandler
Ollie's shares attractive at current levels, says Piper Sandler
OLLI Ollie's Bargain Outlet
$62.58 /

+1.43 (+2.34%)

OLLI Ollie's Bargain Outlet
$62.58 /

+1.43 (+2.34%)

OLLI Ollie's Bargain Outlet
$62.58 /

+1.43 (+2.34%)

Earnings
DocuSign sees FY21 revenue $2.083B-$2.089B, consensus $2.09B » 16:11
12/02/21
12/02
16:11
12/02/21
16:11
DOCU

DocuSign

$234.11 /

+3.05 (+1.32%)

Sees FY21 subscription…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
DOCU DocuSign
$234.11 /

+3.05 (+1.32%)

DOCU DocuSign
$234.11 /

+3.05 (+1.32%)

10/06/21
DocuSign participates in a conference call with Benchmark
10/06/21
DocuSign participates in a conference call with Benchmark
09/03/21 Evercore ISI
DocuSign price target raised to $320 from $285 at Evercore ISI
09/03/21 Needham
DocuSign price target raised to $340 from $275 at Needham
DOCU DocuSign
$234.11 /

+3.05 (+1.32%)

DOCU DocuSign
$234.11 /

+3.05 (+1.32%)

DOCU DocuSign
$234.11 /

+3.05 (+1.32%)

DOCU DocuSign
$234.11 /

+3.05 (+1.32%)

Hot Stocks
White Mountains names Liam Caffrey as CFO, effective March 1, 2022 » 16:11
12/02/21
12/02
16:11
12/02/21
16:11
WTM

White Mountains

$993.43 /

-5.47 (-0.55%)

White Mountains announced…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
    Earnings
    Ulta Beauty reports Q3 EPS $3.94, consensus $2.46 » 16:10
    12/02/21
    12/02
    16:10
    12/02/21
    16:10
    ULTA

    Ulta Beauty

    $381.88 /

    +11.55 (+3.12%)

    Reports Q3 revenue $2.0B,…

    Story temporarily locked.
    To read stories as they happen please subscribe, Login above, or return tomorrow

    Get Free Trial

    ShowHide Related Items >><<
    ULTA Ulta Beauty
    $381.88 /

    +11.55 (+3.12%)

    ULTA Ulta Beauty
    $381.88 /

    +11.55 (+3.12%)

    10/20/21 Cowen
    Ulta Beauty price target lowered to $440 from $490 at Cowen
    10/20/21 BofA
    Ulta Beauty price target lowered to $400 from $430 at BofA
    10/20/21 William Blair
    Ulta Beauty should be bought on yesterday's selloff, says William Blair
    10/20/21 Baird
    Ulta Beauty risk/reward attractive at current levels, says Baird
    ULTA Ulta Beauty
    $381.88 /

    +11.55 (+3.12%)

    ULTA Ulta Beauty
    $381.88 /

    +11.55 (+3.12%)

    ULTA Ulta Beauty
    $381.88 /

    +11.55 (+3.12%)

    ULTA Ulta Beauty
    $381.88 /

    +11.55 (+3.12%)

    Earnings
    Smartsheet raises FY22 EPS view to (32c)-(30c) from (44c)-(36c) » 16:10
    12/02/21
    12/02
    16:10
    12/02/21
    16:10
    SMAR

    Smartsheet

    $60.96 /

    +1.48 (+2.49%)

    Consensus (38c). Raises…

    Story temporarily locked.
    To read stories as they happen please subscribe, Login above, or return in 9 minutes

    Get Free Trial

    ShowHide Related Items >><<
    SMAR Smartsheet
    $60.96 /

    +1.48 (+2.49%)

    SMAR Smartsheet
    $60.96 /

    +1.48 (+2.49%)

    11/23/21 Citi
    Smartsheet price target lowered to $72 from $85 at Citi
    09/08/21 BMO Capital
    Smartsheet price target raised to $90 from $78 at BMO Capital
    09/08/21 Truist
    Smartsheet price target raised to $100 from $85 at Truist
    09/08/21 Needham
    Smartsheet price target raised to $100 from $80 at Needham
    SMAR Smartsheet
    $60.96 /

    +1.48 (+2.49%)

    SMAR Smartsheet
    $60.96 /

    +1.48 (+2.49%)

    SMAR Smartsheet
    $60.96 /

    +1.48 (+2.49%)

    Hot Stocks
    Tilly's reports Q3 SSS up 27.4% vs. pre-pandemic level of Q3 of 2019  16:10
    12/02/21
    12/02
    16:10
    12/02/21
    16:10
    TLYS

    Tilly's

    $14.38 /

    +0.135 (+0.95%)

     
    ShowHide Related Items >><<
    TLYS Tilly's
    $14.38 /

    +0.135 (+0.95%)

    TLYS Tilly's
    $14.38 /

    +0.135 (+0.95%)

    09/03/21 B. Riley
    Tilly's price target raised to $24 from $21 at B. Riley
    08/31/21 Pivotal Research
    Tilly's price target raised to $18 from $17 at Pivotal Research
    06/04/21 B. Riley
    Tilly's price target raised to $21 from $16 at B. Riley
    06/04/21 Pivotal Research
    Tilly's price target raised to $17 from $15 at Pivotal Research
    TLYS Tilly's
    $14.38 /

    +0.135 (+0.95%)

    TLYS Tilly's
    $14.38 /

    +0.135 (+0.95%)

    TLYS Tilly's
    $14.38 /

    +0.135 (+0.95%)

    Earnings
    Ollie's Bargain Outlet reports Q3 EPS 34c, consensus 47c » 16:09
    12/02/21
    12/02
    16:09
    12/02/21
    16:09
    OLLI

    Ollie's Bargain Outlet

    $62.85 /

    +1.7 (+2.78%)

    Reports Q3 revenue…

    Story temporarily locked.
    To read stories as they happen please subscribe, Login above, or return in 9 minutes

    Get Free Trial

    ShowHide Related Items >><<
    OLLI Ollie's Bargain Outlet
    $62.85 /

    +1.7 (+2.78%)

    OLLI Ollie's Bargain Outlet
    $62.85 /

    +1.7 (+2.78%)

    09/08/21
    Fly Intel: Top five analyst upgrades
    09/08/21 Berenberg
    Ollie's Bargain Outlet upgraded to Buy on pullback at Berenberg
    09/08/21 Berenberg
    Ollie's Bargain Outlet upgraded to Buy from Hold at Berenberg
    09/02/21 Piper Sandler
    Ollie's shares attractive at current levels, says Piper Sandler
    OLLI Ollie's Bargain Outlet
    $62.85 /

    +1.7 (+2.78%)

    OLLI Ollie's Bargain Outlet
    $62.85 /

    +1.7 (+2.78%)

    OLLI Ollie's Bargain Outlet
    $62.85 /

    +1.7 (+2.78%)

    Hot Stocks
    Tilly's plans to open 15-20 new stores in 2022 » 16:09
    12/02/21
    12/02
    16:09
    12/02/21
    16:09
    TLYS

    Tilly's

    $14.38 /

    +0.135 (+0.95%)

    The company states:…

    Story temporarily locked.
    To read stories as they happen please subscribe, Login above, or return tomorrow

    Get Free Trial

    ShowHide Related Items >><<
    TLYS Tilly's
    $14.38 /

    +0.135 (+0.95%)

    TLYS Tilly's
    $14.38 /

    +0.135 (+0.95%)

    09/03/21 B. Riley
    Tilly's price target raised to $24 from $21 at B. Riley
    08/31/21 Pivotal Research
    Tilly's price target raised to $18 from $17 at Pivotal Research
    06/04/21 B. Riley
    Tilly's price target raised to $21 from $16 at B. Riley
    06/04/21 Pivotal Research
    Tilly's price target raised to $17 from $15 at Pivotal Research
    TLYS Tilly's
    $14.38 /

    +0.135 (+0.95%)

    TLYS Tilly's
    $14.38 /

    +0.135 (+0.95%)

    TLYS Tilly's
    $14.38 /

    +0.135 (+0.95%)

    Get Full Fly Access

    Breaking market intelligence sent straight to you
    Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
    Up-to-date information on important industry events
    Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
    News focused on the companies in your portfolio
    Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.